Longboard Pharmaceuticals, Inc.
LBPHDelisted Dec 2, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001832168
Longboard Pharmaceuticals, Inc. was delisted on Dec 2, 2024; its insiders filed their last Form 4 on Dec 2, 2024; 125 institutions reported holding it in 13F filings for Q3 2024, worth $1.33B in total; Viking Global Investors was the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Longboard Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- 0 vs. Q4 2021
- Shares held
- 7.61M
- −167.5K (−2.2%) vs. Q4 2021
- Total value
- $40.1M
- +$2.32M (+6.1%) vs. Q4 2021
- New holders
- 1
- 5 more added
- Sold out
- 1
- 5 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LBPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 125 | $1.33B |
| Q2 2024 | 100 | $1.05B |
| Q1 2024 | 105 | $819.5M |
| Q4 2023 | 52 | $99.7M |
| Q3 2023 | 51 | $87.1M |
| Q2 2023 | 50 | $106.7M |
| Q1 2023 | 25 | $51.5M |
| Q4 2022 | 18 | $23.3M |
| Q3 2022 | 19 | $27.0M |
| Q2 2022 | 20 | $23.3M |
| Q1 2022 | 21 | $40.1M |
| Q4 2021 | 21 | $37.8M |
| Q3 2021 | 20 | $68.2M |
| Q2 2021 | 17 | $71.7M |
| Q1 2021 | 22 | $142.8M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Longboard Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,273,221 | $12.1M | 0.93% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 1,512,239 | $7.85M | 0.00% | −512,377−25.3% | Reduced |
| FMR LLC | 1,048,962 | $5.45M | 0.00% | −466,621−30.8% | Reduced |
| Millennium Management LLC | 1,045,929 | $5.43M | 0.01% | +820,372+363.7% | Added |
| Farallon Capital Management, L.L.C. | 810,500 | $4.33M | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 303,749 | $1.62M | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 154,793 | $803.0K | 0.00% | −45,207−22.6% | Reduced |
| OrbiMed Advisors LLC | 113,500 | $606.0K | 0.01% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 70,000 | $363.0K | 0.01% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 62,500 | $334.0K | 0.00% | 00.0% | Unchanged |
| Integral Health Asset Management, LLC | 47,600 | $254.0K | 0.07% | +17,600+58.7% | Added |
| TD Asset Management Inc | 37,624 | $195.0K | 0.00% | −13,226−26.0% | Reduced |
| BlackRock Inc. | 30,669 | $164.0K | 0.00% | +12,576+69.5% | Added |
| Bank of America Corp | 25,367 | $135.0K | 0.00% | +1,842+7.8% | Added |
| Veritable, L.P. | 20,534 | $110.0K | 0.00% | 00.0% | Unchanged |
| Bailard, Inc. | 21,200 | $110.0K | 0.00% | +21,200 | New |
| Laurion Capital Management LP | 20,918 | $109.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 15,177 | $78.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 228 | $1.00K | 0.00% | −2,558−91.8% | Reduced |
| Wells Fargo & Company | 32 | $0 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 5 | $0 | 0.00% | +4+400.0% | Added |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −1,093−100.0% | Sold out |